Clinical Trial Update: Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan [Phase 1]

View source ↗

Summary

Phase 1 study assessing the effect of rifampin on the pharmacokinetics of sitaxsentan has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• RIFAMPIN (RIFAMPIN)
• Sitaxsentan (sitaxsentan)

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Arterial Hypertension | Phase 1 | Status: WITHDRAWN